Frontiers in Pharmacology, published by FRONTIERS MEDIA SA, stands as a leading open-access journal dedicated to advancing the field of pharmacology since its inception in 2010. With its ISSN 1663-9812, the journal is based in Switzerland and maintains a vital role in disseminating innovative research findings that span various disciplines within pharmacology, including pharmacokinetics, toxicology, and pharmacogenetics. In 2023, Frontiers in Pharmacology has achieved an impressive standing within the scientific community, being ranked in the Q1 category for both general and medical pharmacology, highlighting its critical contribution to the field with a Scopus ranking of #41 out of 272 in medical pharmacology and #76 out of 313 in pharmacology, toxicology, and pharmaceutics, placing it in the 75th and 85th percentiles, respectively. Researchers and practitioners benefit from its open-access model, which ensures widespread accessibility to groundbreaking research, fostering collaboration and innovation across the pharmaceutical sciences. With its commitment to excellence, Frontiers in Pharmacology serves as an essential resource for those looking to explore and contribute to the latest advancements in pharmacological research.

DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.

AAPS Journal, published by Springer in the United States, is a leading peer-reviewed journal dedicated to the advancement of research in the field of Pharmaceutical Sciences. With an impressive Q1 rank in its category and a position within the 81st percentile of Scopus rankings, it serves as a vital resource for researchers and professionals seeking to disseminate impactful findings and innovative methodologies. The journal publishes high-quality original research, review articles, and technical reports aimed at addressing the multifaceted challenges in pharmacology, toxicology, and pharmaceutics. Operating under an Open Access model, AAPS Journal ensures broad dissemination of knowledge, contributing to the enhanced visibility and accessibility of research outputs. With a publication window spanning from 1999 to 2024, it continues to shape the future of pharmaceutical research and its applications. Researchers, students, and industry professionals will find a valuable repository of cutting-edge knowledge in this esteemed journal.

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

ADVANCES IN THERAPY is a prestigious peer-reviewed journal published by SPRINGER, specializing in the diverse fields of medicine and pharmacology. Established in 1984, this influential journal has become an essential resource for researchers and professionals, boasting a commendable impact factor and categorically ranking within the Q1 quartile in both Medicine (Miscellaneous) and Medical Pharmacology as of 2023. With an impressive Scopus ranking at #52 out of 272 in the realm of medical pharmacology, it places itself in the top 81st percentile, underscoring its importance in advancing therapeutic knowledge and practices. Although the journal is not open access, it provides invaluable insights and the latest research findings in therapies that significantly impact patient care, making it a vital reference for clinicians, academicians, and students alike.

JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS is a crucial publication in the field of veterinary medicine, dedicated to advancing knowledge and practices related to pharmacology and therapeutic interventions in animals. Published by WILEY, this peer-reviewed journal has been a reliable source of innovative research since its inception in 1978, and it continues to play an integral role in shaping veterinary pharmacology through its commitment to high-quality scientific discourse. With an impact factor reflective of its robust academic standing, the journal is categorized in the Q3 quartile for Pharmacology and Q2 for Veterinary (miscellaneous) as of 2023, highlighting its relevance and significance within these domains. It is indexed in Scopus with commendable rankings, particularly in General Veterinary, where it ranks #45 out of 194, placing it in the 77th percentile. This journal not only offers a platform for original research articles but also caters to the dissemination of practical applications and reviews that are essential for veterinarians, researchers, and students alike in enhancing animal health and welfare. Although not an open-access publication, its contributions remain accessible to those engaged in the veterinary sciences through institutional subscriptions. The journal's enduring legacy and forward-looking approach make it a vital resource for anyone interested in veterinary therapeutics and pharmacology.

The JOURNAL OF PHARMACEUTICAL SCIENCES, published by ELSEVIER SCIENCE INC, stands as a cornerstone in the field of pharmaceutical sciences, offering a platform for innovative research and advancements since its inception in 1961. With an impressive Scopus Rank of #36 out of 183 in the Pharmaceutical Science category, this journal is recognized for its commitment to disseminating high-quality, peer-reviewed studies that significantly contribute to the realms of pharmacology, toxicology, and pharmaceutics. Holding a 2023 Q2 category quartile, it attracts a diverse readership encompassing researchers, industry professionals, and students eager to advance their understanding and expertise. While the journal is not open access, it ensures valuable insights in every issue, making it an essential resource for those dedicated to the evolving landscape of pharmaceutical research. With an impact factor that reflects its relevance and influence, the JOURNAL OF PHARMACEUTICAL SCIENCES continues to shape the discourse in its domain, fostering innovation and collaboration among scholars worldwide.

EXPERT OPINION ON BIOLOGICAL THERAPY, published by Taylor & Francis Ltd, is a prestigious journal that has been a cornerstone in the fields of Clinical Biochemistry, Drug Discovery, and Pharmacology since its inception in 2001. With an impressive impact factor reflecting Q1 status across its categories in 2023, this journal is ranked among the top in both the pharmacology and biochemistry domains, featuring in the 81st and 77th percentiles respectively. This makes it an essential resource for researchers, professionals, and students who are keen on staying at the forefront of biological therapy advancements. The journal encompasses a broad yet focused scope, providing valuable insights into innovative therapeutic strategies and drug development methodologies. Researchers benefit from the rigorous peer-review process and the opportunity to disseminate their findings to a global audience, without the constraints of open access, ensuring the integrity and prestige of published work. As it converges towards 2024, EXPERT OPINION ON BIOLOGICAL THERAPY remains an influential platform for fostering collaboration and discussion in the evolutionary landscape of biological therapies.

Biologics-Targets & Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, specializing in the fields of Gastroenterology, Immunology and Allergy, Oncology, Pharmacology (Medical), and Rheumatology. Launched in 2007, the journal has established a solid reputation for disseminating high-quality research that bridges the gap between laboratory findings and clinical application, offering insights into the therapeutic potential of biologics. With a commendable impact factor and placement in Q1 quartiles across multiple medical domains in 2023, Biologics-Targets & Therapy ranks among the top journals in its categories, providing a platform for researchers and clinicians to share their latest discoveries. Researchers can access articles freely, promoting wider dissemination and collaboration in the scientific community. By publishing innovative studies and reviews, this journal plays a pivotal role in advancing the understanding and therapeutic applications of biologics, making it an essential resource for professionals and students alike.